Core Viewpoint - The company has announced the details of its 2024 restricted stock incentive plan, including the grant date, number of shares, and pricing, which aims to motivate and retain key personnel through equity incentives [2][4][7]. Group 1: Incentive Plan Details - The grant date for the restricted stock is set for December 5, 2025, with the registration completion date on January 9, 2026 [2][22]. - A total of 740,000 shares will be granted, representing 0.2872% of the company's total share capital prior to the grant [2][7]. - The grant price for the restricted stock is set at 10.24 yuan per share [2][7]. Group 2: Approval Process - The company held several meetings to approve the incentive plan, including the seventh board meeting on December 20, 2024, and the first extraordinary general meeting of shareholders on February 5, 2025 [3][4][5]. - The plan has undergone verification by the supervisory board and independent financial advisors, ensuring compliance with relevant regulations [3][5][7]. Group 3: Stock Repurchase and Impact - The restricted stock is sourced from shares repurchased from the secondary market, with a total of 7,209,980 shares repurchased, accounting for 2.80% of the company's total share capital [25][24]. - The stock repurchase was conducted at prices ranging from 17.28 yuan to 18.50 yuan per share, with a total expenditure of approximately 129.41 million yuan [25]. Group 4: Performance Assessment and Conditions - The incentive plan includes performance assessment criteria that must be met for the release of the restricted stock, with evaluations conducted annually over three accounting years [15][19]. - Individual performance assessments will be tailored to different roles, with a grading system to determine eligibility for stock release [19][20]. Group 5: Financial Implications - The issuance of restricted stock will not change the total share capital, thus not affecting the earnings per share [23]. - The company will account for the costs associated with the restricted stock in accordance with relevant accounting standards, adjusting for the number of shares eligible for release based on performance metrics [24][25].

证券代码：002393 证券简称：力生制药 公告编号：2026-001 天津力生制药股份有限公司 关于2024年限制性股票预留部分授予登记完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1.限制性股票预留部分授予日：2025年12月5日 2.限制性股票授予登记完成时间：2026年01月09日 3.限制性股票授予数量：74万股，占授予前公司总股本的比例为0.2872% 4.限制性股票授予登记人数：22人 5.限制性股票来源：从二级市场回购的公司A股普通股股票 6.限制性股票授予价格：10.24元/股 根据天津力生制药股份有限公司(以下简称"力生制药""本公司"或"公司")2025 年第一次临时股东大会授权，公司于2025年12月5日召开第八届董事会第二次会议，审议通 过了《关于调整2024年限制性股票激励计划授予价格暨向激励对象授予预留部分限制性股 票的议案》。根据中国证券监督管理委员会《上市公司股权激励管理办法》、深圳证券交易 所、中国证券登记结算有限责任公司深圳分公司有关规则的规定，公司已完成2024年限制 性股票激励计划（以下简 ...

Core Viewpoint - The article highlights the evolution and modernization of Lisheng Pharmaceutical, emphasizing its commitment to public health and innovation while maintaining its historical roots through the "Three Fish" brand established in 1930 [1][2]. Group 1: Company History and Philosophy - Lisheng Pharmaceutical was founded in 1930 to address the lack of affordable medicine for the public, with the "Three Fish" trademark symbolizing its commitment to making medicine accessible [2]. - The company's philosophy of "for the people" has been a guiding principle, focusing on the integration of raw materials and formulations to ensure affordability and availability of medications [2]. Group 2: Innovation and Product Development - Lisheng has increased its R&D investment, with over 8% of its budget allocated to research in the first half of 2025, resulting in the approval of key products and multiple patent applications [3]. - The company is focusing on high-end generic drugs, modified new drugs for specific populations, and original innovations in critical areas such as synthetic biology and gene therapy [3]. Group 3: Brand Modernization and Marketing Strategy - The "Three Fish" brand has been revitalized to resonate with younger consumers, incorporating cultural narratives and modern marketing strategies such as short online dramas to enhance brand visibility [4][6]. - Lisheng has developed a multi-channel marketing network, utilizing OTC, medical, and online platforms to reach diverse consumer groups effectively [6][7]. - The "Shoubi Mountain" brand is transitioning from a single product to a comprehensive series of antihypertensive medications, with plans to expand its product range significantly [7].

Group 1 - The flu epidemic in China is at a high level, primarily driven by the H3N2 strain, with increased transmission risk due to upcoming population movements during the New Year holiday [1] - Demand for antiviral and symptomatic medications has surged, with a reported over 500% increase in flu-related drug purchases on Alibaba Health and over 100% increase in orders for traditional Chinese medicine on Meituan [1] - The pharmaceutical industry is responding effectively across the supply chain, from vaccine production to drug distribution, indicating a well-coordinated effort to manage the public health challenge [1][2] Group 2 - Vaccine companies are ramping up production, with Hualan Vaccine reporting 55 batches of flu vaccine issued since November, reflecting increased public willingness to get vaccinated [2] - Diagnostic companies like Dian Diagnostics and Kingmed Diagnostics are seeing increased business, supporting the trend of testing before treatment, which enhances rational drug use [2] - The treatment landscape is diversifying, with both chemical and traditional Chinese medicines being utilized, indicating a shift in market dynamics [3][5] Group 3 - Traditional Chinese medicine is gaining traction, with companies like China Resources Sanjiu and Kangyuan Pharmaceutical seeing strong growth in their antiviral product lines [5] - The distribution sector is crucial, with companies like Yiyigou ensuring rapid delivery of essential medications during peak demand periods [5] - The clinical relevance of traditional Chinese medicine is increasing, supported by government policies that endorse its use in flu treatment, leading to a rise in evidence-based research [6][9] Group 4 - Companies are focusing on clinical research to validate the efficacy of traditional Chinese medicines, with Kangyuan Pharmaceutical conducting head-to-head trials against conventional drugs [7][9] - The competitive landscape in the respiratory system traditional Chinese medicine market is diverse, with companies like China Resources Sanjiu and Yiling Pharmaceutical leveraging brand strength and market recognition [9] - As the industry moves towards evidence-based medicine, companies with strong research capabilities and clinical data are likely to capture more market opportunities [9]

Core Viewpoint - On December 30, a total of 7 listed companies will have their restricted shares unlocked, with a total market value of approximately 11.55 billion yuan [1]. Group 1: Company Specifics - Lisheng Pharmaceutical (Stock Code: 002393) will unlock 497,000 shares under equity incentive restrictions [1]. - Xuefeng Technology (Stock Code: 603227) will unlock 97.6172 million shares from the issuance of A-shares to institutional investors [1]. - Su Yan Jingshen (Stock Code: 603299) will unlock 622,700 shares under equity incentive restrictions [1]. - Qianhe Flavoring (Stock Code: 603027) will unlock 2.043 million shares under equity incentive restrictions [1]. - Hongming Co., Ltd. (Stock Code: 301105) will unlock 3.375 million shares from pre-issuance restrictions [1]. - Fulede (Stock Code: 301297) will unlock 200 million shares from pre-issuance restrictions [1]. - Baiwei Storage (Stock Code: 688525) will unlock 11.4 million shares [1].

证券代码：002393 证券简称：力生制药 公告编号：2025-089 天津力生制药股份有限公司 重要提示： 1.本次解除2022年限制性股票激励计划首次授予部分第二次解除限售的股票数量为 583,044股，占公司总股本0.2263%，涉及股东人数66人； 2.本次解除限售的股份上市流通日期为：2025年12月30日。 天津力生制药股份有限公司（以下简称"公司"或"本公司"）于2025年12月05日召开第八 届董事会第二次会议审议通过了《关于2022年限制性股票激励计划首次授予部分第二个解 除限售期解除限售条件成就的议案》。公司董事会认为公司2022年限制性股票激励计划首 次授予部分的第二个解除限售期已符合解除限售条件。 根据公司2022年第五次临时股东大会审议授权及公司2022年限制性股票激励计划相关 规定，公司办理了2022年限制性股票激励计划首次授予部分第二次解除限售并上市流通手 续，现就有关事项说明如下： 一、公司股权激励计划简述及实施情况 关于 2022 年限制性股票激励计划首次授予部分 第二次解除限售并上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 ...

Group 1 - The company announced an investment of 85 million yuan in a structured deposit with a floating return from Industrial Bank's Tianjin branch, with an expected annual yield of 1.20%-1.60% [2] - As of the announcement date, the company has a cash management balance of 155 million yuan, which is below the authorized limit of 600 million yuan [2]

Group 1 - The company Tianjin Development (00882) announced a financial agreement with Industrial Bank for a structured deposit [1] - The agreement involves a principal amount of RMB 85 million, equivalent to approximately HKD 93.41 million [1] - The transaction is part of the company's ongoing financial strategy and investment activities [1]

天津力生制药股份有限公司（以下简称"公司"）于2025年3月19日召开第七届董事会第 五十次会议、2025年4月11日召开2024年度股东大会，审议通过了《关于公司2025年使用 闲置募集资金进行现金管理额度的议案》，同意公司在不影响募集资金投资项目实施的情 况下，使用额度不超过人民币6亿元闲置募集资金购买安全性高、流动性好、由募集户银行 （招商银行、兴业银行或邮储银行）发行的短期理财产品，期限不超过股东大会批准之日 起12个月，在上述额度及期限范围内资金滚动使用。针对上述事项，公司保荐机构发表了 明确的同意意见。具体内容详见公司于2025年3月21日在巨潮资讯网(www.cninfo.com.cn） 披露的《关于公司2025年使用闲置募集资金进行现金管理额度的公告》（公告编号： 2025-025）及《渤海证券关于天津力生制药股份有限公司使用闲置募集资金购买理财产品 的核查意见》。 一、本次进行现金管理购买理财产品情况 公司以募集资金共计8,500万元人民币在兴业银行股份有限公司天津分行（以下简称"兴 业银行"）购买结构性存款。具体情况如下： | 产品名称： | 结构性存款 | | --- | --- | | ...

Group 1 - The core point of the article is that Lisheng Pharmaceutical (002393) announced through an interactive platform that its subsidiary, Central Pharmaceutical, holds a 12.15% stake in Tian Shi Li (600535) Biopharmaceutical Industry Group Co., Ltd [1]